鲁索利替尼
骨髓纤维化
医学
贾纳斯激酶
Janus激酶2
Janus激酶抑制剂
内科学
肿瘤科
骨髓
受体
作者
Claire Harrison,Jean‐Jacques Kiladjian,Haifa Kathrin Al‐Ali,Heinz Gisslinger,Roger J. Waltzman,Viktoriya Stalbovskaya,Mari McQuitty,Deborah Hunter,R. H. Levy,Laurent Knoops,Francisco Cervantes,Alessandro M. Vannucchi,Tiziano Barbui,Giovanni Barosi
标识
DOI:10.1056/nejmoa1110556
摘要
Treatment options for myelofibrosis are limited. We evaluated the efficacy and safety of ruxolitinib, a potent and selective Janus kinase (JAK) 1 and 2 inhibitor, as compared with the best available therapy, in patients with myelofibrosis.
科研通智能强力驱动
Strongly Powered by AbleSci AI